Aragen Life Sciences files IPO papers with Sebi for Rs 800 crore

Aragen Life Sciences, a contract research, development and manufacturing organization (CRDMO), has initiated its IPO process by filing draft papers with India's securities regulator. The filing includes a Rs 800 crore fresh issue of shares alongside an offer for sale component, signaling the company's intent to raise capital from public markets. According to the announcement, the funds raised will be allocated toward reducing the company's debt burden, expanding operational capacity, and acquiring necessary equipment to support growth initiatives.

The company demonstrated strong financial performance during the FY24–FY26 period. Financial results indicated revenue reached Rs 2,178 crore in FY26, while the company reported a net profit of Rs 258 crore for the same fiscal year, reflecting robust operational execution and profitability across this period.

For Indian investors and market participants, this IPO represents an entry point into the contract research and manufacturing sector, which serves the pharmaceutical and biotechnology industries. The CRDMO segment has gained prominence as pharmaceutical companies increasingly outsource research, development, and manufacturing operations to specialized service providers. Aragen's filing demonstrates growing investor appetite for capital markets access among India's contract manufacturing ecosystem, reflecting broader trends in industrialization and the pharmaceutical sector's expansion. The company's demonstrated revenue growth and profitability metrics suggest operational maturity, potentially making it an attractive proposition for institutional and retail investors seeking exposure to India's healthcare and life sciences infrastructure development.

Source: Markets-Economic Times